CVBF is involved with the University of Pittsburgh in developing two vaccines for the coronavirus disease

CVBF is involved with the University of Pittsburgh in developing two vaccines for the coronavirus disease

We are glad to inform you that Consorzio per Valutazioni Biologiche e Farmacologiche will provide its contribution in the fight against COVID-19 emergency. It was recently been entrusted by UPMC – University of Pittsburgh Medical Center with the two studies on COVID-19 which aim to test two  vaccines in the form of a patch (protein subunit) and in intranasal spray (Adenovirus), both are phase I / II studies on healthy volunteers. In particular, the first study is a Phase I/ II Adaptive Clinical Trial to assess safety, tolerability and immunogenicity of PittCoVacc, a Microneedle Array Delivered SARS CoV- 2 Subunit Vaccine, in Healthy Adult Volunteers. The second is an open-label randomized Phase I/II clinical trial of Ad5.SARS-CoV-2-S1. CVBF will be involved in the whole study process, dealing with protocol finalisation, IB and IMPD preparation, submission, study management and monitoring, pharmacovigilance, data management and statistics.

2020-08-17T14:21:38+00:00 07/08/2020|Categories: News|